Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Developments in the Treatment of Schizophrenia: An Expert Roundtable
Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 322-330
Open Access | Times Cited: 23

Showing 23 citing articles:

Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 49
Knowing is Half the Battle: The Factors Leading to Efficient Recruitment of Representative Samples in Schizophrenia Research
Joohyun Yoon, Megan Mayer, Tala Berro, et al.
Pharmaceutical Medicine (2025)
Closed Access | Times Cited: 2
The effects of ketogenic metabolic therapy on mental health and metabolic outcomes in schizophrenia and bipolar disorder: a randomized controlled clinical trial protocol
Calogero Longhitano, Sabine Finlay, Isabella Peachey, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 10
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
Schizophrenia Management: Systematic Review of Current Medications and Phase-3 Agents (2008–2024)
Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Neuroscience Applied (2025) Vol. 4, pp. 105507-105507
Open Access
Is muscarinic receptor agonist effective and tolerant for schizophrenia?
Xiaonan Guo, Rongshan Deng, Jianbo Lai, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction
Jennifer K. Forsyth, Carrie E. Bearden
American Journal of Psychiatry (2023) Vol. 180, Iss. 11, pp. 792-804
Closed Access | Times Cited: 6
Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia
Zijin Feng, Zhijing Hu, Lei Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Inhibition of reactive oxygen species production accompanying alternatively activated microglia by risperidone in a mouse ketamine model of schizophrenia
Risako Fujikawa, Jun Yamada, Shoichiro Maeda, et al.
Journal of Neurochemistry (2024)
Closed Access | Times Cited: 1
Schizophrenia: Disability, Clinical Insights, and Management
Abid Rizvi, Sadia Rehman Safwi, Mohammad Amir Usmani
(2024), pp. 1-12
Closed Access | Times Cited: 1
Los receptores muscarínicos como potencial objetivo terapéutico en la esquizofrenia
José Eduardo López Villa
eNeurobiología (2024) Vol. 15, Iss. 38
Open Access | Times Cited: 1
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry
Joshua T. Kantrowitz, Daniel C. Javitt
Advances in neurobiology (2024), pp. 801-828
Closed Access | Times Cited: 1
Relevance of diet in schizophrenia: a review focusing on prenatal nutritional deficiency, obesity, oxidative stress and inflammation
Viorica Rarinca, Amalia Vasile, Mălina Visternicu, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 1
Is muscarinic receptor agonist effective and tolerant for schizophrenia? A systematic review and meta-analysis
Xiaonan Guo, Rongshan Deng, Jianbo Lai, et al.
Research Square (Research Square) (2024)
Closed Access | Times Cited: 1
The Role of Neuroglia in the Development and Progression of Schizophrenia
Neha S. Rawani, Allen W. Chan, Kathryn G. Todd, et al.
Biomolecules (2024) Vol. 15, Iss. 1, pp. 10-10
Open Access | Times Cited: 1
A lifetime of mental health treatments for people with schizophrenia: update and narrative review
Lynn E. DeLisi
Current Opinion in Psychiatry (2024) Vol. 37, Iss. 3, pp. 140-146
Closed Access
Understanding the Impact of the Dopamine Hypothesis on Schizophrenia
Jelena Stellakis, G. Lyrakos, Georgios Pilafas
Galore International Journal of Health Sciences and Research (2024) Vol. 9, Iss. 2, pp. 41-48
Open Access
Diffusion magnetic resonance imaging for treatment response prediction in schizophrenia spectrum disorders: A systematic review
Mohammadamin Parsaei, Amirmahdi Sheipouri, Paniz Partovifar, et al.
Psychiatry Research Neuroimaging (2024) Vol. 342, pp. 111841-111841
Closed Access
Antipsychotics: beyond dopamine
Mark Greener
Prescriber (2024) Vol. 35, Iss. 4, pp. 5-8
Closed Access
The role of netrin G1-netrin-G-ligand-1 in schizophrenia
Ayooluwa Gabriel Ibiayo, Luo-Zhu Yang, Ingrid Y. Liu
Tzu Chi Medical Journal (2024) Vol. 37, Iss. 1, pp. 1-9
Open Access
How antipsychotics work in schizophrenia: a primer on mechanisms
Jonathan M. Meyer
CNS Spectrums (2024) Vol. 30, Iss. 1
Open Access
A Clinically Oriented Review of New Antipsychotics for Schizophrenia
Maria Luca, Antonina Luca, Alessandro Serretti
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 2637-2649
Open Access
Should We Consider Microbiota-Based Interventions as a Novel Therapeutic Strategy for Schizophrenia? A Systematic Review and Meta-Analysis
Lucas Hassib, Alexandre Kanashiro, João Francisco Cordeiro Pedrazzi, et al.
Brain Behavior & Immunity - Health (2024) Vol. 43, pp. 100923-100923
Open Access
Page 1

Scroll to top